• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人甲状腺良恶性组织的流式细胞术DNA检测

Flow cytometric DNA measurement in benign and malignant human thyroid tissues.

作者信息

Mizukami Y, Nonomura A, Michigishi T, Kosaka T, Noguchi M, Nakamura S, Hashimoto T

机构信息

Pathology Section, Kanazawa University Hospital, Japan.

出版信息

Anticancer Res. 1992 Nov-Dec;12(6B):2213-7.

PMID:1295468
Abstract

The occurrence of aneuploidy in 108 normal, benign and malignant thyroid tissues was evaluated by DNA flow cytometry. Aneuploid cell populations were found in 60% of the papillary carcinomas, 67% of the follicular carcinomas, 52% of the follicular adenomas and in 10% of the multinodular goiters. None of the non-neoplastic thyroid lesions (chronic thyroiditis and Graves' disease) showed aneuploidy. No significant differences in frequency of aneuploidy and DNA index were found between the well-differentiated and trabecular types of the papillary carcinomas (53%; 1.29 +/- 0.10 vs 75%; 1.30 +/- 0.10, respectively), although the latter type of papillary carcinomas have been shown to be associated with a more aggressive clinical behavior. Also no differences in frequency of aneuploidy were noted between the follicular carcinomas and the follicular adenomas, but the DNA index was significantly higher in the former. These findings indicate that flow cytometric analysis of DNA content may not be helpful in the evaluation of the clinical behavior of papillary carcinomas or in the determination of malignancy of follicular tumors, but may be useful in differentiating neoplastic from non-neoplastic thyroid lesions.

摘要

通过DNA流式细胞术评估了108例正常、良性及恶性甲状腺组织中异倍体的发生情况。在60%的乳头状癌、67%的滤泡状癌、52%的滤泡性腺瘤以及10%的结节性甲状腺肿中发现了异倍体细胞群。非肿瘤性甲状腺病变(慢性甲状腺炎和格雷夫斯病)均未显示异倍体。在乳头状癌的高分化型和小梁型之间,异倍体频率和DNA指数未发现显著差异(分别为53%;1.29±0.10与75%;1.30±0.10),尽管后一种类型的乳头状癌已被证明与更具侵袭性的临床行为相关。滤泡状癌和滤泡性腺瘤之间的异倍体频率也未发现差异,但前者的DNA指数显著更高。这些发现表明,DNA含量的流式细胞术分析可能无助于评估乳头状癌的临床行为或确定滤泡性肿瘤的恶性程度,但可能有助于区分肿瘤性与非肿瘤性甲状腺病变。

相似文献

1
Flow cytometric DNA measurement in benign and malignant human thyroid tissues.人甲状腺良恶性组织的流式细胞术DNA检测
Anticancer Res. 1992 Nov-Dec;12(6B):2213-7.
2
[Nuclear DNA in neoplastic pathology of the thyroid gland].[甲状腺肿瘤病理学中的核DNA]
Chir Ital. 1994;46(5):74-6.
3
Comparative studies of nuclear DNA content in benign and malignant thyroid lesions.甲状腺良恶性病变中核DNA含量的比较研究。
Acta Biochim Pol. 2001;48(3):783-93.
4
[Flow cytometric DNA content analysis in thyroid carcinoma].
Zhonghua Zhong Liu Za Zhi. 1991 Mar;13(2):106-9.
5
Surgical pathology.外科病理学
Major Probl Clin Surg. 1980;15:39-69.
6
Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes.甲状腺腺瘤和滤泡癌呈现出两种主要的染色体变化模式。
J Pathol. 2005 Jul;206(3):305-11. doi: 10.1002/path.1772.
7
Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.ras癌基因p21抗原在正常及增殖性甲状腺组织中的表达。
Am J Pathol. 1987 Apr;127(1):60-5.
8
Histopathologic differential diagnosis of the thyroid.甲状腺的组织病理学鉴别诊断
Pathol Annu. 1981;16(Pt 2):357-406.
9
[Flow cytometric DNA measurements of thyroid carcinomas].
Gan No Rinsho. 1989 Jul;35(8):886-90.
10
Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms.良性和恶性甲状腺肿瘤中染色体非整倍性的频率和程度。
Int J Cancer. 1990 Jan 15;45(1):16-20. doi: 10.1002/ijc.2910450105.

引用本文的文献

1
A non-diploid DNA status is linked to poor prognosis in renal cell cancer.非整倍体 DNA 状态与肾细胞癌预后不良相关。
World J Urol. 2021 Mar;39(3):829-837. doi: 10.1007/s00345-020-03226-8. Epub 2020 May 2.
2
Nuclear DNA analysis and prognosis in carcinoma of the thyroid gland. A nationwide study in Iceland on carcinomas diagnosed 1955-1990.甲状腺癌的核DNA分析与预后。冰岛一项关于1955年至1990年诊断出的甲状腺癌的全国性研究。
Virchows Arch. 1994;425(4):349-55. doi: 10.1007/BF00189572.